PMV PHARMACEUTICALS, INC. Additional Paid in Capital, Common Stock
PMV PHARMACEUTICALS, INC. (PMVP) had Additional Paid in Capital, Common Stock of $554.16 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-14
- 2026-06-30: Additional Paid in Capital, Common Stock $554.16M.
- 2026-03-31: Additional Paid in Capital, Common Stock $552.47M.
- 2025-12-31: Additional Paid in Capital, Common Stock $551.08M.
- 2025-09-30: Additional Paid in Capital, Common Stock $549.33M.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2026-06-30 | $554.16M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $552.47M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $551.08M 10-Q · filed 2026-08-14 |
| 2025-09-30 | $549.33M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $547.94M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $546.17M 10-Q · filed 2025-05-09 |
| 2024-12-31 | $544.65M 10-K · filed 2026-03-06 |
| 2024-09-30 | $543.21M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $540.99M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $538.08M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $535.47M 10-K · filed 2025-03-03 |
| 2023-09-30 | $532.21M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $495.74M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $490.46M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $487.52M 10-K · filed 2024-02-29 |
| 2022-09-30 | $483.92M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $481.46M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $478.67M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $476.36M 10-K · filed 2023-03-01 |
| 2021-09-30 | $474.30M 10-Q · filed 2021-11-12 |
| 2021-06-30 | $472.20M 10-Q · filed 2021-08-13 |
| 2021-03-31 | $469.79M 10-Q · filed 2021-05-14 |
| 2020-12-31 | $469.00M 10-K · filed 2022-03-01 |
| 2020-09-30 | $468.40M 10-Q · filed 2020-11-13 |
| 2019-12-31 | $4.97M 10-K · filed 2021-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |